Mustang Bio, Inc.
377 Plantation Street
Worcester
MA
01605
United States
Tel: 781-652-4500
Website: http://www.mustangbio.com/
Email: info@mustangbio.com
141 articles about Mustang Bio, Inc.
-
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
3/4/2021
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Mustang’s management team will participate in three virtual investor conferences in March 2021.
-
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
2/26/2021
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced its support for Rare Disease Day®
-
It was a busy week for clinical trial updates. Here’s a look.
-
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
2/2/2021
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy
-
There were two reported cases of trials restarting and one pausing this week. Here’s a look.
-
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
12/21/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that a Phase 1 single-center, two-arm cl
-
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
12/7/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”
-
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin LymphomaCall to be held Wednesday, December 9, 2020, at 1:00 p.m. EST
12/1/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (KOL) call on MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma on Wednesday, December 9, 2020, at 1:00 p.m
-
Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
11/24/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Commission (“EC”) issued a positive opinion on its application for Orphan Drug Designation for Mustang’s lentiviral gene therapy for the treatment of X-linke
-
Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
11/23/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announc
-
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
11/6/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. “Mustang had an eventful third quarter on the regulatory front, as the U.S.
-
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
11/4/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”), have been s
-
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate CancerData presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat
10/26/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that one patient‘s experience on the Phase 1 trial of MB-105,
-
Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020
10/1/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at Chardan’s Virtual 4 th Annual Genetic Medicines Conference 2020 on M
-
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
10/1/2020
Safety and efficacy to be evaluated in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia and high-risk myelodysplastic syndrome
-
Mustang Bio to Participate in Three September 2020 Virtual Investor Conferences
9/10/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020.
-
Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
9/2/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease
-
Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients
8/31/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-207,
-
Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit
8/17/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in the two-day Fortress Biotech (“Fortress”) Virtual Summit taking place on Tuesday, August
-
Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency
8/17/2020
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked s